Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Foundation Medicine Inc    FMI

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Foundation Medicine : Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Foundation Medicine, Inc. FMI

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 07:35pm CET

By a News Reporter-Staff News Editor at Managed Care Weekly Digest -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the September 26, 2017 deadline in the class action lawsuit filed on behalf of investors who purchased Foundation Medicine, Inc. ("Foundation" or the "Company") (NASDAQ: FMI) securities between February 26, 2014 and November 3, 2015, inclusive (the "Class Period"). Foundation investors have until September 26, 2017 to file a lead plaintiff motion. To obtain information or participate in the class action, please visit the Foundation case page on our website at www.glancylaw.com/case/foundation-medicine-inc (see also Glancy Prongay and Murray LLP).

The Complaint filed in this class action alleges that, during the Class Period, the Company made false and misleading statements and/or failed to disclose adverse information regarding the Company's business and prospects. Specifically, the complaint alleges that the defendants made false and/or misleading statements regarding: (i) the reimbursement process and likelihood of coverage for Foundation's tumor tests by Medicare; and (ii) the Company's financial guidance. As a result of these false statements, Foundation common stock traded at artificially inflated prices during the Class Period.

On July 29, 2015, the Company disclosed that "clinical volume growth was affected by slower than anticipated progress towards obtaining a local coverage determination from our regional Medicare Administrative Contractor (MAC) and by some competitive noise in the market" and that, as such, the Company was "adjusting" its guidance for clinical volume and annual revenues. Then, on November 3, 2015, the Company disclosed a further revision to the already reduced number of clinical tests it expected to report for 2015.

On this news, the price of Foundation common stock fell $6.62 per share, to close at $17.31 per share on November 4, 2015.

Follow us for updates on Twitter: twitter.com/GPM_LLP.

If you purchased shares of Foundation during the Class Period you may move the Court no later than September 26, 2017 to ask the Court to appoint you as lead. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. View source version on businesswire.com: http://www.businesswire.com/news/home/20170925006403/en/

Keywords for this news article include: Medicare, Legal Issues, Health Policy, Glancy Prongay and Murray LLP.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on FOUNDATION MEDICINE INC
11/01 FOUNDATION MEDICINE : reports 3Q loss
11/01 FOUNDATION MEDICINE : Management's Discussion and Analysis of Financial Conditio..
11/01 FOUNDATION MEDICINE, INC. : Results of Operations and Financial Condition, Finan..
11/01 FOUNDATION MEDICINE : Announces 2017 Third Quarter Results and Recent Highlights
10/26 FOUNDATION MEDICINE : to Present Validation for FoundationOne CDx™, a Comp..
10/19 FOUNDATION MEDICINE : Appoints Tom Civik as Chief Commercial Officer
10/17 FOUNDATION MEDICINE : Study Shows Genomic Profiling Can Help Improve Treatment o..
10/16 FOUNDATION MEDICINE : to Present Validation for FoundationOne CDx™, a Comp..
10/12 FOUNDATION MEDICINE : Receives Approval from the State of New York for its Found..
10/12 FOUNDATION MEDICINE : Researchers at Foundation Medicine Inc. Have Reported New ..
More news
News from SeekingAlpha
11/01 Foundation Medicine's (FMI) CEO Troy Cox on Q3 2017 Results - Earnings Call T..
11/01 Foundation Medicine beats by $0.20, beats on revenue
10/31 Notable earnings after Wednesday?s close
10/10 Foundation Medicine taps Civik as chief commercial officer
09/29 Move Over Yellen! It's Tax Cut Time!
Financials ($)
Sales 2017 142 M
EBIT 2017 -159 M
Net income 2017 -139 M
Finance 2017 44,5 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 12,5x
EV / Sales 2018 10,0x
Capitalization 1 820 M
Chart FOUNDATION MEDICINE INC
Duration : Period :
Foundation Medicine Inc Technical Analysis Chart | FMI | US3504651007 | 4-Traders
Technical analysis trends FOUNDATION MEDICINE INC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 5
Average target price 40,7 $
Spread / Average Target -19%
EPS Revisions
Managers
NameTitle
Troy Cox Chief Executive Officer & Director
Steven J. Kafka President & Chief Operating Officer
Michael J. Pellini Chairman
Jason Ryan CFO & Principal Accounting Officer
Vincent A. Miller Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
FOUNDATION MEDICINE INC183.62%1 820
CELLTRION, INC.--.--%24 558
INCYTE CORPORATION5.19%22 258
IQVIA HOLDINGS INC37.36%22 074
LONZA GROUP59.52%19 560
ALNYLAM PHARMACEUTICALS, INC.240.57%12 538